Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer
Status:
Completed
Trial end date:
2021-04-16
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well talazoparib works in treating patients with homologous
recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer that has
come back after previous treatment. Talazoparib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth.